Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells.
about
Role of nuclear receptors in breast cancer stem cellsLipid-sensors, enigmatic-orphan and orphan nuclear receptors as therapeutic targets in breast-cancerp63 transcriptionally regulates the expression of matrix metallopeptidase 13.A RXR ligand 6-OH-11-O-hydroxyphenanthrene with antitumour properties enhances (-)-epigallocatechin-3-gallate activity in three human breast carcinoma cell lines.A high-content assay to identify small-molecule modulators of a cancer stem cell population in luminal breast cancer.Mechanism of retinoic acid-induced transcription: histone code, DNA oxidation and formation of chromatin loops.Peroxisome proliferator activated receptor-α/hypoxia inducible factor-1α interplay sustains carbonic anhydrase IX and apoliprotein E expression in breast cancer stem cells.Therapeutic Effects of PPAR α on Neuronal Death and Microvascular Impairment.Interleukin-6 and pro inflammatory status in the breast tumor microenvironmentFlubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells.Peritoneal expression of Matrilysin helps identify early post-operative recurrence of colorectal cancer.Activation of peroxisome proliferator-activated receptor gamma is crucial for antitumoral effects of 6-iodolactone.Basal/HER2 breast carcinomas: integrating molecular taxonomy with cancer stem cell dynamics to predict primary resistance to trastuzumab (Herceptin).Loss of 5-lipoxygenase activity protects mice against paracetamol-induced liver toxicityMolecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatmentTherapeutic strategies targeting cancer stem cellsThe PPARγ agonist efatutazone increases the spectrum of well-differentiated mammary cancer subtypes initiated by loss of full-length BRCA1 in association with TP53 haploinsufficiency.Combined Treatment with Epigenetic, Differentiating, and Chemotherapeutic Agents Cooperatively Targets Tumor-Initiating Cells in Triple-Negative Breast Cancer.Actin-binding protein alpha-actinin 4 (ACTN4) is a transcriptional co-activator of RelA/p65 sub-unit of NF-kB.Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity.Chemoprevention of head and neck squamous cell carcinoma through inhibition of NF-κB signaling.Unlocking Doors without Keys: Activation of Src by Truncated C-terminal Intracellular Receptor Tyrosine Kinases Lacking Tyrosine Kinase Activity.Targeting cancer stem cells and signaling pathways by phytochemicals: Novel approach for breast cancer therapyEpigenetic up-regulation of ribosome biogenesis and more aggressive phenotype triggered by the lack of the histone demethylase JHDM1B in mammary epithelial cells.Concise Review: Emerging Drugs Targeting Epithelial Cancer Stem-Like Cells.A truncated-Flt1 isoform of breast cancer cells is upregulated by Notch and downregulated by retinoic acid.Tanshinone IIA inhibits breast cancer stem cells growth in vitro and in vivo through attenuation of IL-6/STAT3/NF-kB signaling pathways.Carbonic Anhydrase 9 mRNA/microRNA34a Interplay in Hypoxic Human Mammospheres.Evaluation of Antioxidant Intakes in Relation to Inflammatory Markers Expression Within the Normal Breast Tissue of Breast Cancer Patients.PPARγ and RXR ligands disrupt the inflammatory cross-talk in the hypoxic breast cancer stem cells niche
P2860
Q26750359-D7009180-FC56-4E8D-9CC4-01368F4AD93AQ26764743-75B4D066-75B4-4262-8BBD-DD359D43865AQ33576855-450047E9-5B93-471A-B5D5-3C49267D9817Q33810548-4ECF09E4-0EF4-499F-A2A0-770A23997529Q34150752-13F844D5-B2A8-456D-8E1D-13DE749265D0Q34248924-9BEF0689-C6E9-4132-ABD3-4F81804E89BFQ34571496-38B3FDF8-37A8-40C8-9675-777CB75BAE7AQ35078274-1DCA9343-D756-414D-AF15-05798FDAB804Q35427020-4A0137FC-D282-4059-BF02-50E580AF607EQ35742530-5CE2BD74-09B3-41E7-83D7-E3F47CE8D7BDQ35955331-79A5DC08-9DF7-4369-ABF3-5BC58FAA8695Q36068879-89764E27-FA73-48B3-87CA-CE164E4221CBQ36618624-4131FBCA-F6E9-4EC7-A293-6EA6F8138920Q36744182-2E3417C5-5A71-4832-82F2-DAA143AB0E21Q36745391-BC499BE5-6A66-420A-A98A-4C97FE5EBD2CQ36887716-B269AB49-FDEC-4C70-8ECD-1EDE7E86CFACQ36888347-A30F42F7-D910-4581-9B05-A7BDF0E34FCDQ36918202-E1AD5471-8626-455E-A527-313C30B3AD95Q37016599-0C010B7D-49A8-4104-A4EC-FA4113455570Q37662428-A8DE5D2A-0244-432A-A9F9-D752D56FEAFDQ37728618-252EE112-FF6A-4E52-815B-D0654C83FAF0Q38673511-5CE984E0-4378-4180-9B4B-E7E82338A464Q38823095-C733E8F2-D761-4718-8C28-9221FFB45EE9Q38834035-E289E054-4572-43E8-851D-2CE2A127806CQ39112034-0D914956-29E4-4FE1-AE05-768CE093D680Q39117307-5FBF5D9A-A76C-4D42-876E-F72ABBAADC7BQ39171958-3A504BEB-4409-4B55-81A6-B1DC095B938BQ40339127-67FECF6C-6D00-4D95-8041-0B8C46DC6680Q48655410-4FB35BA5-03E8-486D-AABA-BD370A4F988CQ56972352-DA522AE2-EB44-435D-8C1F-2E14F9CA3828
P2860
Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Nuclear receptors agonists exe ...... l of breast cancer stem cells.
@ast
Nuclear receptors agonists exe ...... l of breast cancer stem cells.
@en
type
label
Nuclear receptors agonists exe ...... l of breast cancer stem cells.
@ast
Nuclear receptors agonists exe ...... l of breast cancer stem cells.
@en
prefLabel
Nuclear receptors agonists exe ...... l of breast cancer stem cells.
@ast
Nuclear receptors agonists exe ...... l of breast cancer stem cells.
@en
P2093
P2860
P50
P356
P1476
Nuclear receptors agonists exe ...... al of breast cancer stem cells
@en
P2093
A Sanguinetti
M Taffurelli
T Guarnieri
P2860
P2888
P304
P356
10.1038/CDD.2011.207
P577
2012-01-20T00:00:00Z